Medtronic Financial Statements (MDT)
|
|
|
|
Report date
|
|
|
25.06.2021 |
23.06.2022 |
22.06.2023 |
20.06.2024 |
20.06.2025 |
|
24.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
30 117 |
|
|
|
|
|
26 557 |
|
Operating Income, bln rub |
|
|
4 484 |
|
|
|
|
|
4 903 |
|
EBITDA, bln rub |
? |
|
7 522 |
|
|
|
|
|
7 081 |
|
Net profit, bln rub |
? |
|
3 606 |
|
|
|
|
|
3 557 |
|
|
OCF, bln rub |
? |
|
6 240 |
|
|
|
|
|
4 757 |
|
CAPEX, bln rub |
? |
|
1 355 |
|
|
|
|
|
1 416 |
|
FCF, bln rub |
? |
|
4 885 |
|
|
|
|
|
3 341 |
|
Dividend payout, bln rub
|
|
|
3 120 |
|
|
|
|
|
2 731 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
86.5% |
|
|
|
|
|
76.8% |
|
|
OPEX, bln rub |
|
|
15 150 |
|
|
|
|
|
11 299 |
|
Cost of production, bln rub |
|
|
10 483 |
|
|
|
|
|
10 354 |
|
R&D, bln rub |
|
|
2 493 |
|
|
|
|
|
2 202 |
|
Interest expenses, bln rub |
|
|
925.0 |
|
|
|
|
|
538.0 |
|
|
Assets, bln rub |
|
|
93 083 |
90 981 |
90 948 |
89 981 |
91 680 |
|
91 485 |
|
Net Assets, bln rub |
? |
|
51 428 |
52 551 |
51 483 |
50 214 |
48 024 |
|
48 985 |
|
Debt, bln rub |
|
|
26 389 |
24 114 |
24 364 |
25 024 |
28 516 |
|
28 071 |
|
Cash, bln rub |
|
|
10 817 |
10 573 |
7 959 |
8 005 |
8 965 |
|
8 383 |
|
Net debt, bln rub |
|
|
15 572 |
13 541 |
16 405 |
17 019 |
19 551 |
|
19 688 |
|
|
Ordinary share price, rub |
|
|
130.9 |
104.4 |
91.0 |
79.7 |
84.2 |
|
78.6 |
|
Number of ordinary shares, mln |
|
|
1 345 |
|
|
|
|
|
1 282 |
|
|
Market cap, bln rub |
|
|
176 074 |
0 |
0 |
0 |
0 |
|
100 747 |
|
EV, bln rub |
? |
|
191 646 |
13 541 |
16 405 |
17 019 |
19 551 |
|
120 435 |
|
Book value, bln rub |
|
|
-8 273 |
-3 545 |
-4 786 |
-3 997 |
-5 380 |
|
-3 242 |
|
|
EPS, rub |
? |
|
2.68 |
|
|
|
|
|
2.77 |
|
FCF/share, rub |
|
|
3.63 |
|
|
|
|
|
2.61 |
|
BV/share, rub |
|
|
-6.15 |
|
|
|
|
|
-2.53 |
|
|
EBITDA margin, % |
? |
|
25.0% |
|
|
|
|
|
26.7% |
|
Net margin, % |
? |
|
12.0% |
|
|
|
|
|
13.4% |
|
FCF yield, % |
? |
|
2.77% |
0.00% |
0.00% |
0.00% |
0.00% |
|
3.32% |
|
ROE, % |
? |
|
7.01% |
0.00% |
0.00% |
0.00% |
0.00% |
|
7.26% |
|
ROA, % |
? |
|
3.87% |
0.00% |
0.00% |
0.00% |
0.00% |
|
3.89% |
|
|
P/E |
? |
|
48.8 |
|
|
|
|
|
28.3 |
|
P/FCF |
|
|
36.0 |
|
|
|
|
|
30.2 |
|
P/S |
? |
|
5.85 |
|
|
|
|
|
3.79 |
|
P/BV |
? |
|
-21.3 |
0.00 |
0.00 |
0.00 |
0.00 |
|
-31.1 |
|
EV/EBITDA |
? |
|
25.5 |
|
|
|
|
|
17.0 |
|
Debt/EBITDA |
|
|
2.07 |
|
|
|
|
|
2.78 |
|
|
R&D/CAPEX, % |
|
|
184.0% |
|
|
|
|
|
155.5% |
|
|
CAPEX/Revenue, % |
|
|
4.50% |
|
|
|
|
|
5.33% |
|
| Medtronic shareholders |
